TheraCryf has announced the filing of a new manufacturing process patent covering the production of its lead Ox-1 asset which is on track for clinical trial readiness by the end of this year. When granted, the patent should extend TheraCryf's effective period of exclusivity for Ox-1 to 2046, materially beyond existing patent protection through 2038/39 covering the US, Europe and China. That additional protection, should enhance the commercial attractiveness of Ox-1 significantly, likely further increasing partnering and acquisition interest.
